Centerline Biomedical
Cleveland, US · Delaware corporation · 2 known investors
Centerline Biomedical develops IOPS®, a 510(k)-cleared endovascular navigation technology that provides real-time 3D image guidance for physicians performing catheterization and other endovascular procedures. The technology is designed to reduce radiation exposure and improve procedural accuracy for interventional cardiologists, vascular surgeons, and other interventionalists.
Founders & leadership
GK
Gulam KhanExecutive Officer, Director
IE
Indrani EglestonExecutive Officer
VG
Vikash GoelExecutive Officer
VK
Vinod K. GoelExecutive Officer
AS
Akhil SaklechaDirector
PR
Phil RackliffeExecutive Officer, Director
MW
Michael WhitmanDirector
TS
Todd SchwarzingerDirector
MW
Mitch WolfDirector
AM
Arnaud MarieDirector
Investors · 2
Competitors · 10
by search overlapDiabetes Prevention Program80 shared keywords
HealthiNation68 shared keywords
Cleveland Clinic, 202264 shared keywordsCleveland Clinic is a patient-centered academic medical center providing clinical care, research, and medical education. The organization offers services ranging from primary care and virtual visits to specialized treatment, clinical trials, and advanced medical research.
Mayo Clinic59 shared keywords
Fda53 shared keywords
PlushCare45 shared keywordsPlushCare is a telemedicine platform providing online consultations with board-certified physicians for weight loss management, urgent care, chronic disease treatment, and therapy. Patients can receive prescriptions, including GLP-1 medications, and therapy sessions through phone or video consultation.
Blink Health45 shared keywords
analog37 shared keywordsRxList is an online drug information reference that provides details on prescription medications, drug classifications, comparisons, vitamins and supplements. It offers consumer tools such as a drug interaction checker and pill identifier.
Honeybee Health37 shared keywords
Healthline36 shared keywordsHealthline publishes medically reviewed health and wellness content for general consumers, drawing on a network of medical reviewers. It operates as a consumer health media and information platform.
Companies competing with Centerline Biomedical for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$10.8MraisedApr 2025 · 8 investors · BiotechnologyRule 506(b)
▶$10.8MraisedApr 2025 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael WhitmanDirector
- Todd SchwarzingerDirector
- Mitch WolfDirector
- Gulam KhanExecutive Officer, Director
- Arnaud MarieDirector
- Indrani EglestonExecutive Officer
- Offering amount
- $15M
- Amount sold
- $10.8M
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13.7MraisedNov 2023 · 65 investors · BiotechnologyRule 506(b)
▶$13.7MraisedNov 2023 · 65 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jim ZalarDirector
- Karen ShanahanDirector
- Jai N. GuptaExecutive Officer, Director
- Vinod K. GoelExecutive Officer, Director
- Gulam KhanExecutive Officer
- Vikash GoelExecutive Officer
- Offering amount
- $13.7M
- Amount sold
- $13.7M
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.7MraisedNov 2023 · 106 investors · BiotechnologyRule 506(b)
▶$12.7MraisedNov 2023 · 106 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Phil RackliffeExecutive Officer, Director
- Vikash GoelExecutive Officer
- Jai N. GuptaDirector
- Vinod K. GoelExecutive Officer, Director
- Jim ZalarDirector
- Gulam KhanExecutive Officer
- Offering amount
- $12.7M
- Amount sold
- $12.7M
- Sales commissions
- $846.6K
- Placement agents
- Paulson Investment Company, LLC
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$34.7MraisedNov 2023 · 22 investors · BiotechnologyRule 506(b)
▶$34.7MraisedNov 2023 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Vikash GoelExecutive Officer
- Vinod K. GoelExecutive Officer
- Todd SchwarzingerDirector
- Mitch WolfDirector
- Gulam KhanExecutive Officer
- Akhil SaklechaDirector
- Phil RackliffeExecutive Officer, Director
- Offering amount
- $34.7M
- Amount sold
- $34.7M
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $224.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2018 | $223.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.